tiprankstipranks
Trending News
More News >
QuidelOrtho (QDEL)
NASDAQ:QDEL
US Market
Advertisement

QuidelOrtho (QDEL) Earnings Dates, Call Summary & Reports

Compare
1,738 Followers

Earnings Data

Report Date
Feb 18, 2026
After Close (Confirmed)
Period Ending
2025 (Q4)
Consensus EPS Forecast
0.56
Last Year’s EPS
0.63
Same Quarter Last Year
Moderate Buy
Based on 7 Analysts Ratings

Earnings Call Summary

Q3 2025
Earnings Call Date:Nov 05, 2025|
% Change Since:
|
Earnings Call Sentiment|Neutral
The earnings call showcased a strong performance in organic sales growth, cost savings, and regional successes, despite challenges from declining COVID and donor screening revenues, negative cash flow due to system conversion, and a significant goodwill impairment charge.
Company Guidance
In the third quarter of 2025, QuidelOrtho reported organic sales growth of 5%, excluding COVID-related sales and the U.S. donor screening business. The company's adjusted EBITDA expanded to 25% of sales, reflecting over $140 million in cost savings, and it is on track to achieve sustainable mid- to high 20s EBITDA margins. The Labs business saw a 4% increase in revenue, with the immunohematology segment growing by 5% and the point-of-care Triage product line achieving 7% growth. However, respiratory revenue declined due to a 63% drop in COVID revenue, and flu revenue decreased by 8% year-over-year. QuidelOrtho's international growth was led by Latin America, which grew 21% overall. Adjusted EBITDA for the quarter was $177 million, with an adjusted EBITDA margin improvement of 180 basis points from the previous year. The company also reported an adjusted diluted EPS of $0.80 and is maintaining its focus on sustainable, profitable growth.
Organic Sales Growth
QuidelOrtho reported an organic sales growth of 5%, excluding COVID sales and the U.S. donor screening business exit, demonstrating the strength of their diversified global diagnostics portfolio.
Improved Adjusted EBITDA
Adjusted EBITDA expanded to 25% of sales, driven by margin improvement initiatives that delivered over $140 million in cost savings.
Strong Regional Performance
Excluding COVID, Latin America led with 21% overall growth, and 22% in labs. Japan, Asia Pacific, and China each grew approximately 5%, and Europe, Middle East, and Africa grew 3%.
High-Sensitivity Troponin Assay
FDA clearance for VITROS high-sensitivity troponin assay was achieved in 90 days, enhancing the cardiac panel's competitiveness.
Cost Savings Achievements
The company achieved significant cost savings, with adjusted EBITDA margin improving by 180 basis points from the prior year.

QuidelOrtho (QDEL) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

QDEL Earnings History

Report Date
Fiscal Quarter
Forecast / EPS
Last Year's EPS
EPS YoY Change
Press Release
Slides
Play Transcript
Feb 18, 2026
2025 (Q4)
0.56 / -
0.63
Nov 05, 2025
2025 (Q3)
0.52 / 0.80
0.85-5.88% (-0.05)
Aug 05, 2025
2025 (Q2)
<0.01 / 0.12
-0.07271.43% (+0.19)
May 07, 2025
2025 (Q1)
0.59 / 0.74
0.4468.18% (+0.30)
Feb 12, 2025
2024 (Q4)
0.59 / 0.63
1.17-46.15% (-0.54)
Nov 07, 2024
2024 (Q3)
0.27 / 0.85
0.9-5.56% (-0.05)
Jul 31, 2024
2024 (Q2)
-0.23 / -0.07
0.26-126.92% (-0.33)
May 08, 2024
2024 (Q1)
0.39 / 0.44
1.8-75.56% (-1.36)
Feb 13, 2024
2023 (Q4)
2.04 / 1.17
1.76-33.52% (-0.59)
Nov 01, 2023
2023 (Q3)
0.60 / 0.90
1.85-51.35% (-0.95)
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed

QDEL Earnings-Related Price Changes

Report Date
Price 1 Day Before
Price 1 Day After
Percentage Change
Nov 05, 2025
$27.37$21.26-22.32%
Aug 05, 2025
$23.68$23.44-1.01%
May 07, 2025
$25.85$36.46+41.04%
Feb 12, 2025
$39.94$41.65+4.28%
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does QuidelOrtho (QDEL) report earnings?
QuidelOrtho (QDEL) is schdueled to report earning on Feb 18, 2026, After Close (Confirmed).
    What is QuidelOrtho (QDEL) earnings time?
    QuidelOrtho (QDEL) earnings time is at Feb 18, 2026, After Close (Confirmed).
      Where can I see when companies are reporting earnings?
      You can see which companies are reporting today on our designated earnings calendar.
        What companies are reporting earnings today?
        You can see a list of the companies which are reporting today on TipRanks earnings calendar.
          What is QDEL EPS forecast?
          QDEL EPS forecast for the fiscal quarter 2025 (Q4) is 0.56.

            QuidelOrtho (QDEL) Earnings News

            QuidelOrtho (NASDAQ:QDEL) Plunges as Q4 Results Disappoint
            Premium
            Market News
            QuidelOrtho (NASDAQ:QDEL) Plunges as Q4 Results Disappoint
            2y ago
            What am I Missing?
            Make informed decisions based on Top Analysts' activity
            Know what industry insiders are buying
            Get actionable alerts from top Wall Street Analysts
            Find out before anyone else which stock is going to shoot up
            Get powerful stock screeners & detailed portfolio analysis